Deerfield Management Company, L.P.

Institutional investor · Portfolio as of Q1 2021

Q1 2021 biggest moves
  • EWTXEWTX

    Edgewise Therapeutics

    New listing

    2.7% of portfolio

  • BSXBSX

    Boston Scientific

    7× the shares

    now 2.3% of portfolio

  • NKTXNKTX

    Nkarta

    Sold out

    was 1.7% of portfolio

  • NBIXNBIX

    Neurocrine Biosciences

    New

    1.5% of portfolio

121 changes in all

Top Holdings133 positions

Checking export access…
Activity:
??
INVITAE CORPDelisted
Bond
163.4M$245.8M5.2%——
3 qtrssince 2020-Q3
Unchanged
0
VTRS

Viatris Inc.

17.2M$240.6M5.1%$14.63-23.76%
2 qtrssince 2020-Q4
Increased
65
??
NEVRO CORPDelisted
Bond
115.8M$168.4M3.5%——
6 qtrssince 2019-Q4
Unchanged
0
149.6M$154.4M3.2%——
3 qtrssince 2020-Q3
Unchanged
0
80M$132M2.8%——
1 qtr
New
78
EWTX

Edgewise Therapeutics, Inc.

3.9M$127.8M2.7%$32.500.00%
1 qtr
New
78
CNC

Centene Corporation

2M$126.9M2.7%$60.25+6.08%
6 qtrssince 2019-Q4
Decreased
0
BSX

Boston Scientific Corporation

2.9M$110.4M2.3%$38.27+1.01%
2 qtrssince 2020-Q4
Increased
83
10.5M$104.2M2.2%——
2 qtrssince 2020-Q4
Increased
81
ALXN
ALXNDelisted

ALEXION PHARMACEUTICALS INC

579,248$88.6M1.9%——
4 qtrssince 2020-Q2
Unchanged
0
BIIB

Biogen Inc.

310,000$86.7M1.8%$244.86+14.25%
2 qtrssince 2020-Q4
Decreased
0
AHCO

AdaptHealth Corp.

2.3M$83.7M1.8%$18.96+93.88%
6 qtrssince 2019-Q4
Increased
58
6.8M$82.2M1.7%——
2 qtrssince 2020-Q4
Increased
75
PCRX

Pacira BioSciences, Inc.

1.2M$81.7M1.7%$37.51+86.84%
5 qtrssince 2020-Q1
Increased
52
??
INSULET CORPDelisted
Bond
57.6M$76.1M1.6%——
2 qtrssince 2020-Q4
Unchanged
0
LRMR

Larimar Therapeutics, Inc.

5.1M$75.2M1.6%$12.85+13.70%
4 qtrssince 2020-Q2
Unchanged
0
NBIX

Neurocrine Biosciences, Inc.

725,000$70.5M1.5%$97.250.00%
1 qtr
New
68
MIRM

Mirum Pharmaceuticals, Inc.

3.4M$68.4M1.4%$24.52-19.17%
6 qtrssince 2019-Q4
Unchanged
0
??
INSMED INCDelisted
Bond
61M$68M1.4%——
5 qtrssince 2020-Q1
Unchanged
0
RVMD

Revolution Medicines, Inc.

1.4M$65.9M1.4%$22.58+103.16%
5 qtrssince 2020-Q1
Increased
48
$4.8B
AUM
133
Positions
Q1 2021
Filing
HI rating · 1.0/5
Quarterly 13F Value Change
Reported 13F value ($B)
Reported 13F values and quarter-over-quarter reported value changes; not investment returns.
QuarterReported value in US dollarsReported value change
2020-Q1$3,151,113,0000.539146165786%
2020-Q2$3,433,887,0008.97378164477%
2020-Q3$4,106,901,00019.5991889075%
2020-Q4$5,059,782,00023.2019471616%
2021-Q1$4,758,345,000-5.95750963184%
Activity profile
$ moved · Q1'21
New35%Increased18%Decreased14%Exited33%
Composition
Equity vs derivatives
Equity100%Puts0%Calls0%
Holding period
Avg 2.8 quarters
<1Q29%1-4Q32%1-2Y30%2Y+10%

Deerfield Management Company, L.P. manages $4.8B across 133 positions as of Q1 2021. Top holdings: INVITAE CORP (5.2%), VTRS (5.1%), NEVRO CORP (3.5%). Fund DNA: Balanced Allocator. HoldingsIntel Score: 1/5.0.

Top holdings by portfolio weight

Total AUM$5B
INVITAE CORP5.16%
VTRS5.06%
NEVRO CORP3.54%
AERIE PHARMA3.25%
Bridgebio Ph2.77%
EWTX2.69%
CNC2.67%
BSX2.32%
DFP HEALTHCA2.19%
ALXN1.86%
Other1.82%

Portfolio allocation by GICS sector

Sectors3
Healthcare71.07%
Unknown28.60%
Consumer Cyclical0.33%

Behavioral investing profile

Checking access…
Balanced Allocator- primarily Healthcare, Unknown
Compare DNA across all funds
7-dimension, SEC 13F-derived research score
Weak(1.0 / 5.0)
Holdings P&L32
Conviction55
Concentration66
Checking access…

Position Outcomes

Best and worst performing positions by estimated return

Cost basis estimates based on full filing history using quarter-end prices. Actual transaction prices are not disclosed in 13F filings.

Accumulation Streaks

Positions with 2+ consecutive quarters of increases - persistent directional conviction.

Security
5Q
BCRXBCRXBioCryst Pharmaceuticals, Inc.
Q3 2025 → Q3 2026+10.8M shares+$87M
3Q
TNGXTNGXTango Therapeutics, Inc.
Q1 2026 → Q3 2026+2.3M shares+$103.5M
2Q
BMRNBMRNBioMarin Pharmaceutical Inc.
Q2 2026 → Q3 2026+1.2M shares+$73.4M
Checking access…

Famous Investors' Portfolios

What the most-followed managers hold, and what they bought and sold each quarter.

Photo credits

Photo:“Warren Buffett at the 2015 SelectUSA Investment Summit”by USA International Trade Administration, cropped,public domainvia Wikimedia Commons

Photo:Leopold Aschenbrenner

Photo:“Cathie Wood ARK Invest Photo”by Caroline Wood, cropped,CC BY-SA 4.0via Wikimedia Commons

Photo:“Valeant Pharmaceuticals' Business Model (headshot)”by Senate Democrats, cropped,CC BY 2.0via Wikimedia Commons

Photo:Harlem Children's Zone

Photo:Mohnish Pabrai

Photo:“Peter Thiel on March 5 2026”by Kantei (The Prime Minister Office of Japan), cropped,CC BY 4.0via Wikimedia Commons

Photo:Charlotte FC

Photo:Ray Dalio

Photo:Himalaya Capital

Photo:Jonathan Kozowyk, Robin Hood

Photo:“Brad Gerstner at the White House 2025 (54581192563)”by The White House, cropped,public domainvia Wikimedia Commons

Photo:SuperReturn North America

Photo:Liz Linder, Harvard Kennedy School

Photo:Oaktree Capital Management

Photo:The Everglades Foundation

Photo:George Soros

Photo:Benjamin Meaker, Point72

Photo:Fundsmith

Photo:“Kenneth C. Griffin photo”by Paul Elledge, cropped,CC BY-SA 4.0via Wikimedia Commons

Data sourced from SEC EDGAR 13F filings. Not financial advice. Full disclaimer

Verify source filings on SEC EDGAR

Optional analytics helps us improve. How it’s used